[1] Baars A, Claessen AM, van den Eertwegh AJ, et al. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma:experience in 81 patients. Ann Oncol, 2000,11:965-970.
[2] Bystryn JC, Zeleniuch-Jacquotte A, Oratz R,et al. Double-blind trial of a polyvalent,shed-antigen, melanoma vaccine. Clin Cancer Res, 2001,7:1882-1887.
[3] Tsioulias GJ, Gupta RK, Tisman G, et al.Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol,2001,8:190-191.
[4] Lewis JJ, Janetzki S, Schaed S, et al. Evaluation of CD8 (+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer,2000,87:391-398.
[5] Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase Ⅰ trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant:immunologic and clinical outcomes. Clin Cancer Res,2001,7:3012-3024.
[6] Ragupathi G, Meyers M, Adluri S, et al. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-laetone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer,2000,85:659-666.
[7] Chapman PB, Morrissey DM, Panageas KS,et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients usingGM2-keyhole limpet hemocyanin + QS21 vaccine:a dose-response study. Clin Cancer Res, 2000,6:874-879.
[8] Gibbs P, Hutchins AM, Dorian KT, et al.MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Melanoma Res, 2000,10:259-264.
[9] Valmori D, Dutoit V, Rubio-Godoy V, et al.Frequent cytolytic T-cell responses to peptide MAGE-A10 (254-262) in melanoma.Cancer Res, 2001,61:509-512.
[10] Hunger RE, Brand CU, Streit M, et al.Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol, 2001,10:161-167.
[11] Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an antiidiotype antibody mimicking disialoganglioside GD2. J Clin Oncol, 2000,18:376-384.
[12] Alfonso M, Diaz A, Hernandez AM, et al.An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol, 2002,168:2523-2529.
[13] Kirkwood JM, Mascari RA, Edington HD, et al. Analysis of therapeutic and immunologic effects of R (24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer, 2000,88:2693-2702.
[14] Mitchell MS, Darrah D, Yeung D, et al.Phase Ⅰ trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol,2002,20:1075 - 1086.
[15] Banchereau J, Palucka AK, Dhodapkar M,et al. Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor-derived dendritic cell vaccine. Cancer Res, 2001,61:6451-6458.
[16] Dudley ME, Wunderlich J, Nishimura MI,et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother, 2001,24:363-373.
[17] Dreau D, Foster M, Hogg M, et al. Angiogenic and immune parameters during recombinant interferon-alpha 2b adjuvant treatment in patients with melanoma. Oncol Res, 2001,12:241-251.
[18] Kirkwood JM, Ibrahim J, Lawson DH, et al.High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma:results of the Multicenter Eastern Cooperative Oncology Group Phase Ⅱ Trial E2696.J Clin Oncol, 2001,19:1430-1436.
[19] 李玉生,屈凤莲,李峻峰,等.恶性黑色素瘤的生物治疗和生物化疗.中华肿瘤杂志,2000,22:430-431.
[20] Atzpodien J, Neuber K, Kamanabrou D, et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha:results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer, 2002,86:179-184.
[21] Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol, 2001,19:3836-3847.
[22] Weiss GR, Fehrenkamp SH, Tokaz LK, et al. Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4. Dermatology, 1996,192:283-285.
[23] Kusumoto M, Umeda S, Ikubo A, et al.Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother, 2001,50:373-381.
[24] Osanto S, Schiphorst PP, Weijl NI, et al.Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther, 2000,11:739-750.
[25] Newton DA, Romano C, Gattoni-Celli S.Semiallogeneic cell hybrids as therapeutic vaccines for cancer. J Immunother, 2000,23:246-254.
[26] Trefzer U, Weingart G, Chen Y, et al. Hybrid cell vaccination for cancer immune therapy:first clinical trial with metastatic melanoma. Int J Cancer, 2000,85:618-626. |
